New drug cocktail shows promise against tough cancers

NCT ID NCT02499328

Completed Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested combinations of the immunotherapy drug durvalumab with other drugs (danvatirsen, AZD5069, or tremelimumab) in 340 adults with advanced solid tumors or head and neck cancer. The goal was to find safe doses and see if the combinations shrink tumors. The trial has completed, and results may help design future treatments.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (MEDI4736), danvatirsen (AZD9150), AZD5069, and tremelimumab
What this could lead to: If successful, this could point toward a new combination treatment option for advanced head and neck cancer.
What could go wrong: This is an early-phase trial (Phase 1b/2) with a small number of participants, so results may not apply to all patients. Side effects from combining multiple drugs are possible.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer head and neck squamous cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS & METASTATIC SQUAMOUS CELL CARCINOMA OF THE HEAD AND NECK

Contacts and locations

Locations

Research Site

Birmingham, Alabama, 35294, United States
Research Site

Duarte, California, 91010, United States
Research Site

La Jolla, California, 92093, United States
Research Site

Los Angeles, California, 90024, United States
Research Site

Los Angeles, California, 90089, United States
Research Site

Orange, California, 92868-3298, United States
Research Site

San Francisco, California, 94158, United States
Research Site

Denver, Colorado, 80218, United States
Research Site

Plantation, Florida, 33324, United States
Research Site

Sarasota, Florida, 34232, United States
Research Site

Lafayette, Indiana, 47905, United States
Research Site

Boston, Massachusetts, 02111, United States
Research Site

Detroit, Michigan, 48201, United States
Research Site

Billings, Montana, 59101, United States
Research Site

Morristown, New Jersey, 07960, United States
Research Site

Cincinnati, Ohio, 45267-2827, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Fairfax, Virginia, 22031, United States
Research Site

Seattle, Washington, 98109, United States
Research Site

Antwerp, 2020, Belgium
Research Site

Brussels, 1000, Belgium
Research Site

Brussels, 1200, Belgium
Research Site

Edegem, 2650, Belgium
Research Site

Namur, 5000, Belgium
Research Site

Berlin, 12200, Germany
Research Site

Cologne, 50670, Germany
Research Site

Dresden, 1307, Germany
Research Site

Frankfurt, 60488, Germany
Research Site

Hamburg, 20246, Germany
Research Site

Hanover, 30625, Germany
Research Site

Jena, 07743, Germany
Research Site

München, 81675, Germany
Research Site

Milan, 20133, Italy
Research Site

Barcelona, 08035, Spain
Research Site

Hospitalet deLlobregat, 08907, Spain
Research Site

Madrid, 28040, Spain
Research Site

Madrid, 28041, Spain
Research Site

Toledo, 45004, Spain
Research Site

Birmingham, B15 2TH, United Kingdom
Research Site

London, SE1 9RT, United Kingdom
Research Site

London, SW3 6JB, United Kingdom
Research Site

Manchester, M20 4BX, United Kingdom
Research Site

Surrey, SM2 5PT, United Kingdom
Research Site

Taunton, TA1 5DA, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.